

## Supplemental Figure S1.


A

	Cellular proliferation						GST-ABL kinase autophosphorylation	
	K562 cells			LAMA cells			IC <sub>50</sub>	Reference
	IC <sub>50</sub>	Concentrations used in washout studies	Fold over IC <sub>50</sub>	IC <sub>50</sub>	Concentrations used in washout studies	Fold over IC <sub>50</sub>		
dasatinib	0.67 nM	10 nM 100 nM	14.9 149	0.14 nM	10 nM 100 nM	71.4 714	3.7 nM	(1)
ponatinib	1.7 nM	10 nM 100 nM	6.0 60.3	0.32 nM	10 nM 100 nM	31.3 313	8.9 nM	(1)
nilotinib	18.8 nM	500 nM 5000 nM	26.6 266	8.3 nM	500 nM 5000 nM	60.2 602	21.3 nM	(1)
imatinib	319 nM	500 nM 5000 nM	1.6 15.7	103 nM	500 nM 5000 nM	4.9 48.5	430 nM	(1)
DCC-2036	27.1 nM	500 nM 5000 nM	18.5 185	12.3 nM	500 nM 5000 nM	40.7 407	29.0 nM	(2)

## REFERENCES:


(1) O'Hare et al., *Cancer Cell* 2009; 16 (5):401-412.(2) Eide et al., *Cancer Research* 2011; 71 (9):3189-3195.

B







Supplemental Figure S3.



## Supplemental Figure S4.





# Supplemental Figure S5.



Newly diagnosed CML (12/061)

Newly diagnosed CML (11/442)



**A**



**B**




**C**



## Supplemental Figure S6.

CML M-BC harboring BCR-ABL<sup>T315I</sup> (07/103)

A



B

